%0 Journal Article
%A Huynh-Le, Minh-Phuong
%A Fan, Chun Chieh
%A Karunamuni, Roshan
%A Walsh, Eleanor I
%A Turner, Emma L
%A Lane, J Athene
%A Martin, Richard M
%A Neal, David E
%A Donovan, Jenny L
%A Hamdy, Freddie C
%A Parsons, J Kellogg Kellogg
%A Eeles, Rosalind A
%A Easton, Douglas F
%A Kote-Jarai, Zsofia
%A Amin Al Olama, Ali
%A Benlloch Garcia, Sara
%A Muir, Kenneth
%A Grönberg, Henrik
%A Wiklund, Fredrik
%A Aly, Markus
%A Schleutker, Johanna
%A Sipeky, Csilla
%A Tammela, Teuvo
%A Nordestgaard, Børge Grønne
%A Key, Timothy J
%A Travis, Ruth C
%A Pharoah, Paul D P
%A Pashayan, Nora
%A Khaw, Kay-Tee
%A Thibodeau, Stephen N
%A McDonnell, Shannon K
%A Schaid, Daniel J
%A Maier, Christiane
%A Vogel, Walther
%A Luedeke, Manuel
%A Herkommer, Kathleen
%A Kibel, Adam S
%A Cybulski, Cezary
%A Wokolorczyk, Dominika
%A Kluzniak, Wojciech
%A Cannon-Albright, Lisa A
%A Brenner, Hermann
%A Schöttker, Ben
%A Holleczek, Bernd
%A Park, Jong Y
%A Sellers, Thomas A
%A Lin, Hui-Yi
%A Slavov, Chavdar Kroumov
%A Kaneva, Radka P
%A Mitev, Vanio I
%A Batra, Jyotsna
%A Clements, Judith A
%A Spurdle, Amanda B
%A Teixeira, Manuel R
%A Paulo, Paula
%A Maia, Sofia
%A Pandha, Hardev
%A Michael, Agnieszka
%A Mills, Ian G
%A Andreassen, Ole A
%A Dale, Anders M
%A Seibert, Tyler M
%T A genetic risk score to personalize prostate cancer screening, applied to population data.
%J Cancer epidemiology, biomarkers & prevention
%V 29
%N 9
%@ 1538-7755
%C Philadelphia, Pa.
%I AACR
%M DKFZ-2020-01118
%P 1731-1738
%D 2020
%Z 2020 Sep;29(9):1731-1738
%X A polygenic hazard score (PHS)-the weighted sum of 54 SNP genotypes-was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening.UK population incidence data (Cancer Research UK) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using hazard ratios estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age-when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-years-standard risk)-was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups.The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-years-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age.PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS.Personalized genetic risk assessments could inform prostate cancer screening decisions.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32581112
%R 10.1158/1055-9965.EPI-19-1527
%U https://inrepo02.dkfz.de/record/156801